Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Cancer
- cell therapy
- Drug Discovery
- Radiation
- Therapeutic
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 295067
This drug discovery collaboration agreement is to identify up to three additional, undisclosed targets, and any resulting product candidates.
Targeted radionuclide therapy (also called molecular radiotherapy) involves a radioactive drug called a radiopharmaceutical that targets cancer cells. Radiopharmaceuticals typically consist of a radioactive atom (also known as a radionuclide) combined with a cell-targeting molecule that seeks and destroys cancer cells.
IPSCIO Record ID: 1351
Licensee shall have the right to grant sublicenses under the license to employ Affiliates and Third Parties.
Patents
SK979 – Targeted alpha particle therapy with DOTA-based complexes of Ac225 – US Provisional application number 60/232,909.
SK933 – Liposome encapsulation of Ac225 – US Provisional application number 60/212,186.
SK352 – Alpha emitting constructs and used thereof – US Provisional application number 60/086,772.
SK712 – Bi-213 Generator and used thereof – US Provisional application number 60/079,902.
The field shall mean all therapeutic use of Licensed Products in humans and animals.
IPSCIO Record ID: 263763
Licensor grants to Licensee, to the extent Licensor is legally able to do so, a non-exclusive, sublicensable, license in the Territory under such issued letters patent for Licensee to develop, make, have made, use, sell, offer for sale or import Compounds and Products in the Territory.
For the Covenants/Companion Diagnostic, Licensor grants a non-exclusive license, with the right to grant sublicenses, under Licensor Patent Rights, Licensor Know-How, and Companion Diagnostic Trademarks to market and promote the Companion Diagnostic in the Field in the Territory for use in connection with the Product and use the Companion Diagnostic in any way necessary or reasonably useful in order for Licensee to exercise the license granted by Licensor.
This agreement is to develop and commercialize a novel investigational therapeutic candidate vintafolide (EC145).
Vintafolide is a proprietary, injectable, conjugate consisting of folate (vitamin B9) linked to a potent vinca alkaloid chemotherapy agent, desacetylvinblastine monohydrazide (DAVLBH).
Etarfolatide is a folate-targeted molecular imaging agent that is being developed as a noninvasive method to identify tumors that over-express folate receptors.
Product(s) means any pharmaceutical or biological preparation.
Vintafolide is designed to preferentially target the chemotherapy agent to fast growing cancer cells that actively take up folate via the folate receptor. The folate receptor is expressed in a wide variety of cancers including ovarian, NSCLC, breast, colon and kidney.
